Caribou Biosciences (CRBU) Assets Average (2021 - 2026)

Caribou Biosciences (CRBU) has 6 years of Assets Average data on file, last reported at $162.2 million in Q1 2026.

• On a quarterly basis, Assets Average fell 44.74% year-over-year to $162.2 million in Q1 2026; TTM through Mar 2026 was $162.2 million, a 44.74% decrease from a year earlier, with the FY2025 full-year figure at $244.3 million, down 34.45% from the prior year.
• Assets Average for Q1 2026 stood at $162.2 million, down from $185.2 million in the prior quarter.
• Over the last five years, Assets Average for CRBU reached as high as $444.9 million in Q4 2023 and fell as low as $162.2 million in Q1 2026.
• Historically, Assets Average has averaged $342.6 million across 5 years, with a median of $360.6 million in 2023.
• Across the five-year window, Assets Average surged 32.21% in 2022 and plunged 44.74% in 2026, its largest moves.
• Year by year, Assets Average stood at $386.3 million in 2022, then increased by 15.16% to $444.9 million in 2023, then fell by 26.08% to $328.8 million in 2024, then plunged by 43.69% to $185.2 million in 2025, then slipped by 12.42% to $162.2 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $162.2 million in Q1 2026, $185.2 million in Q4 2025, and $207.9 million in Q3 2025.